ReviewPediatric nephrology (Berlin, Germany)2026
Neonatal acute kidney injury: where are we now?
Review in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Novel biomarkers for acute kidney injury in high-risk pediatric populations: a systematic review.Renal failure · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal acute kidney injury (AKI) affects approximately one third of newborns admitted to neonatal intensive care units and is associated with increased morbidity and mortality. The etiology of neonatal AKI is multifactorial, with prematurity and low birth weight being major risk factors. Diagnosis can be challenging, as current criteria rely on serum creatinine and urine output which have considerable limitations. The need for a timely and correct detection of AKI has led to the search for biomarkers, such as neutrophil gelatinase-associated lipocalin, cystatin C, kidney injury molecule-1 and interleukin-18, which have yet to be implemented in current clinical practice. Fluid accumulation is associated with poor outcomes and has been challenging to identify in neonates. New techniques, such as bioeletrical impedance analysis and point of care ultrasound, have just started being used in the pediatric population, and may be of interest in neonates, as well. Several studies have shown that neonatal AKI can have long term consequences and manifest as chronic kidney disease in children and adults, and therefore should warrant close monitoring and adequate follow up.
Indexed as
Identifiers
41236623What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.